NetcareNTC
NTC logo
Fair Value
R18.44
Share price23 Jun
R18.610.9% overvalued intrinsic discount
Loading
1Y37.95%
7D0.054%

Data Analytics Platform Will Optimize Clinical Operations By End Of 2024

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
28 Jan 25
Updated
23 Jun 26
Views
84
Not Invested

Last Update 23 Jun 26

Fair value Increased 3.25%

NTC: Dividend Progress And New Leadership Will Shape Steady Forward Outlook

Netcare's analyst price target has been nudged higher from ZAR17.86 to ZAR18.44. Analysts point to updated assumptions on revenue growth, profit margins and future P/E expectations as the core drivers of the revision.

What's in the News

  • Netcare declared an interim dividend of ZAR0.44 per ordinary share for the six months ended 31 March 2026, compared with ZAR0.36 per share a year earlier, sourced from income reserves.
  • The interim dividend is scheduled to be paid on 13 July 2026 to shareholders on the register at close of business on 10 July 2026. Shares will trade ex dividend from 8 July 2026.
  • The dividend will be subject to a 20% local dividend withholding tax, resulting in a net dividend of ZAR0.352 per share for shareholders who are not exempt, and ZAR0.44 per share for those who are exempt.
  • Netcare appointed Melanie Da Costa as CEO Designate with effect from 1 June 2026, ahead of her taking over as Chief Executive Officer on 1 January 2027, succeeding Dr Richard Friedland.
  • Dr Friedland will step down from the Board on 31 December 2026 and will continue as a strategic advisor to the Board and CEO on a consultancy basis from 1 January to 30 June 2027.

Valuation Changes

  • Fair Value: ZAR17.86 to ZAR18.44, indicating a small upward adjustment to the estimated value for Netcare.
  • Discount Rate: 17.07% to 17.09%, a very marginal change in the rate used to discount future cash flows.
  • Revenue Growth: 4.48% to 4.57%, reflecting slightly higher projected ZAR revenue expansion in the updated model.
  • Net Profit Margin: 8.60% to 8.49%, a small reduction in the margin assumption despite higher revenue growth expectations.
  • Future P/E: 12.29x to 12.82x, implying a modestly higher multiple applied to Netcare's projected earnings.
3 viewsusers have viewed this narrative update

Key Takeaways

  • Digitization and data-driven strategies optimize operations, reduce costs, and enhance net margins and competitive positioning through improved clinical efficiency.
  • Environmental and product expansion strategies aim for sustainable growth, yielding new revenue streams and positive stakeholder perception.
  • Rising expenses and modest growth in patient activities pressure margins, while high interest rates and strategic costs could further strain profitability and earnings.

Catalysts

About Netcare
    An investment holding company, operates private hospitals in South Africa.
What are the underlying business or industry changes driving this perspective?
  • Completion of the digitization rollout with significant operational efficiencies achieved, surpassing initial forecasts, is expected to generate cost savings and improve EBITDA margins by leveraging digital efficiencies in clinical and operational processes. This contributes directly to enhancing net margins.
  • The second phase of Netcare's strategy, data-driven clinical efficiency, involves implementing a data analytics platform due to complete by the end of 2024. This platform will optimize clinical operations, reduce costs, improve patient outcomes, and thus enhance both revenue and margins in the upcoming years.
  • The ongoing rollout of environmental strategies aims to achieve ambitious emission and resource reduction targets by 2030. This sustainability initiative can lead to lower utility costs and position the company positively among environmentally conscious stakeholders, impacting net margins favorably.
  • Continued growth in NetcarePlus, designed to expand healthcare access beyond traditional medical schemes, leverages a broadening portfolio of products that target an underserved market, anticipated to generate additional revenue streams in the primary care segment.
  • Strategic expansion involving new specialist admitting privileges and investments in start-up businesses, such as the pathology network, is expected to foster increased patient volumes and surgical cases, directly impacting revenue growth and enhancing the company's competitive positioning in the healthcare market.
Netcare Earnings and Revenue Growth

Netcare Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Netcare's revenue will grow by 4.6% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 6.5% today to 8.5% in 3 years time.
  • Analysts expect earnings to reach ZAR 2.6 billion (and earnings per share of ZAR 1.97) by about June 2029, up from ZAR 1.8 billion today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 12.8x on those 2029 earnings, up from 11.9x today. This future PE is greater than the current PE for the ZA Healthcare industry at 11.5x.
  • Analysts expect the number of shares outstanding to decline by 1.24% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 17.09%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • The company's margins are under pressure due to increased electricity costs despite benefits from reduced diesel expenditure, which may negatively impact overall profitability.
  • While occupancy levels have improved, the growth in patient days is relatively modest at 0.3%, which may limit potential revenue increases in the short term.
  • The primary care division has experienced a decline in patient visits by 3.1%, reflecting financially constrained consumers, which could affect future revenue in this segment.
  • The net financial expenses increased by 20.9% due to high prevailing interest rates and higher net debt, which could squeeze net margins and earnings further if interest rates remain elevated.
  • Ongoing strategic costs and the potential delay in realizing benefits from data-driven initiatives and patient-centered care may strain near-term earnings and limit margin improvements.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of ZAR18.44 for Netcare based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ZAR20.3, and the most bearish reporting a price target of just ZAR14.6.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be ZAR30.8 billion, earnings will come to ZAR2.6 billion, and it would be trading on a PE ratio of 12.8x, assuming you use a discount rate of 17.1%.
  • Given the current share price of ZAR17.7, the analyst price target of ZAR18.44 is 4.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Netcare?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

R18.44
vs R18.610.9% overvalued intrinsic discount
PastFuture037b2015201820212024202620272029Revenue R30.8bEarnings R2.6b
4.6%
Revenue growth
8.5%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Netcare

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Adequate balance sheet and fair value.

Market capR22.1b
PB2.2x
Estimated Growth4.5%
Dividend Yield4.6%
Full analysis

CEO & management

Richard Friedland
CEO
6.2yrs
CEO Tenure

An investment holding company, operates private hospitals in South Africa.